Profil and Evaluation of Resistant Tuberculosis Drug’s Side Effect in Diabetes and Non Diabetes Mellitus Patient at RSUD Arifin Achmad
DOI:
https://doi.org/10.36497/jri.v40i3.119Keywords:
MDR-TB, Diabetes Melitus, side effects, conversion, outcomeAbstract
Backgrounds: Diabetes mellitus (DM) increases the risk of reactivation of tuberculosis included multi-resistant drug tuberculosis (MDR-TB). This situation is threatening Riau province due to the high prevalence of DM. Since 2014 Arifin Achmad Hospital as a referral hospital of MDR-TB management. It’s treatment especially in DM patients, requires an evaluation of both outcome and side effects. This evaluation needs to be compared with non-DM MDR TB patients. The aim of this study was to evaluate and analyse patient’s characteristic, conversion of smear or culture, drugs side effect and treatment outcome. Methods: This is a cross sectional retrospective study in RSUD Arifin Achmad Pekanbaru on April-October 2018. Sample of this study were all patients from 2014 – 2017. This study was divided into 2 groups, namely the DM and non-DM groups, then analysed the differences between the two groups Results: There were 113 MDR TB patients had its treatment, which 61% of the patients were male. Baseline data show 26.5% of MDR TB patients have comorbid DM. The most common side effects were nausea and vomiting (100%) in all subjects. In the MDR TB DM group, we found included: well controlled plasma glucose level was 33.3%, severe side effects was16.7%, conversion in the second month 40% and cured or complete treatment was 30%. Conclusions: As many as 26,5% of MDR TB patients had DM comorbidity. There were no differences in the percentage of drugs side effects, smear conversion in the second month and treatment outcome between MDR TB DM and MDR TB non-DM group. (J Respir Indo. 2020; 40(3): 156-62)Downloads
References
Global Tuberculosis Report 2016. http://apps.who.int/medicinedocs/en/d/Js23098en/
Reviono, Kusnanto P, Eko V, Pakiding H, Nurwidiasih D. Multidrug Resistant Tuberculosis (MDR-TB): Tinjauan Epidemiologi dan Faktor Risiko Efek Samping Obat Anti Tuberkulosis. MKB.2014:46(14):189-196.
Murray JF, Schraufnagel DE, Hopewell PC. Treatment of Tuberculosis A Historical Perspective. Ann Am Thorac Soc. 2015; 12 (12): 1749–1759.
Saleri N, Dembe´le´ SM, Villani P, Carvalho ANC, Cusato M, Bonkoungou V. et.all. Systemic Exposure to Rifampicin in Patients With Tuberculosis and Advanced HIV Disease During Highly Active Antiretroviral Therapy in Burkina Faso. J Antimicrob Chemother 2012; 67: 469 –472.
Keshavjee S, and Farmer PE. Tuberculosis, Drug Resistance, and the History of Modern Medicine. N Engl J Med. 2012;367:931-6. DOI: 10.1056/NEJMra1205429
World Health Organization. Collaborative framework for care and control of Tuberculosis and diabetes. 2011
Rosdiana D. Multidrug Resistant Tuberculosis with Diabetes Mellitus as a Comorbidity: a case report. J Kesehat Melayu. 2017;1(1):45-51.
Bashar M, Alcabes P, Rom WN, Condos R. Increase Incidence Multidrug Resistance Tuberculosis in Diabetic Patient on the Bellevue Chest Service 1987 to 1997. Chest. 2001;120:1514-9.
Suradi PW, Surjanto E. Hubungan Antara Diabetes Mellitus dengan Multidrug Resistant pada Penderita Tuberkulosis Di Surakarta. J Respir Indo. 2004;25:24-8.
Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff TH et al. The Effect of Type 2 Diabetes Mellitus on the Presentation and Treatment Response of Pulmonary Tuberculosis. Clinical Infectious Disease. 2007;45:428-35
Zhang Y, Yew WW. Mechanisms of Drug Resistance in Mycobacterium Tuberculosis. Int J Tuberc Lung Dis 2009;13(11):1320–30.
Rumende CM. Risk Factors for Multidrug-resistant Tuberculosis. Acta Med Indones - Indones J Intern Med. 2018: 1-2.
American Diabetes Association. Criteria for Type 2 Diabetes Diagnosis. Diabetes Care Journal. 2015; 38 (1): S8–S16
Wijayanto A, Burhan E, Nawas A, Rochsismandoko. Faktor Terjadinya Tuberkulosis Paru pada Pasien Diabetes Mellitus Tipe 2. J Respir Indo. 2015 Jan 1; 35 (1): 1-11
Kementerian Kesehatan RI. Petunjuk Teknis Pengobatan Pasien TB Resistan Obat dengan Paduan Standar Jangka Pendek di Fasyankes TB Resistan Obat. Kementerian Kesehatan RI, 2017.
El Din MAT, El Maraghy AA, Hay A. Adverse Reactions Among Patients Being Treated for Multi-Drug Resistant Tuberculosis at Abbassia Chest Hospital. Egyptian Journal of Chest Diseases and Tuberculosis. 2015; 64. 939-52.
Holland DP, Sanders GD, Hamilton CD, Stout JE. Strategies for Treating Latent Multiple-Drug Resistant Tuberculosis: A Decision Analysis. PLoS ONE. 2012 Jan; 7(1): 1-2
Liang L, Wu Q, Gao L, Hao Y, Liu C, Xie Y, Sun H et al. Factors Contributing to the High Prevalence of Multidrug-Resistant Tuberculosis: a study from China. Thorax. 2012;67:632-8. doi:10.1136/thoraxjnl-2011-200018.
Downloads
Additional Files
Published
Issue
Section
License
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
